CJ-42794 is primarily utilized in research settings as a potent and selective antagonist for the prostaglandin EP4 receptor. Its application is significant in studying inflammatory processes, as EP4 receptors play a crucial role in mediating inflammation and pain. Researchers use CJ-42794 to investigate the pathways and mechanisms involved in conditions such as arthritis, cancer, and cardiovascular diseases. By blocking EP4 receptors, it helps in understanding the potential therapeutic effects of EP4 inhibition in reducing inflammation and tumor growth. Additionally, it is employed in preclinical studies to explore its efficacy in managing chronic pain and other inflammatory disorders.